Replimune (REPL) EV to EBITDA (2018 - 2026)
Powered by 
Analysis
Replimune (REPL) EV to EBITDA (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn |
| 10 | Replimune | 1.45 Bn | 1.45 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10.76 |
| Mar 31, 2026 | -4.96 |
| Dec 31, 2025 | -7.03 |
| Sep 30, 2025 | -0.06 |
| Jun 30, 2025 | -3.53 |
| Mar 31, 2025 | -3.38 |
| Dec 31, 2024 | -6.00 |
| Sep 30, 2024 | -5.39 |
| Jun 30, 2024 | -2.54 |
| Mar 31, 2024 | -1.38 |
| Dec 31, 2023 | -0.90 |
| Sep 30, 2023 | -8.05 |
| Jun 30, 2023 | -14.92 |
| Mar 31, 2023 | -7.88 |
| Dec 31, 2022 | -22.20 |
| Sep 30, 2022 | -11.72 |
| Jun 30, 2022 | -11.42 |
| Mar 31, 2022 | -12.76 |
| Dec 31, 2021 | -28.93 |
| Sep 30, 2021 | -32.59 |